HAMI3379
HAMI3379 性质
| 沸点 | 797.7±60.0 °C(Predicted) |
|---|---|
| 密度 | 1.24±0.1 g/cm3(Predicted) |
| 储存条件 | Store at -20°C |
| 溶解度 | 乙醇中≤5mg/ml；DMSO 中≤20mg/ml；二甲基甲酰胺中≤20mg/ml |
| 形态 | 结晶固体 |
| 酸度系数(pKa) | 4.20±0.10(Predicted) |
| 颜色 | 白色至米白色 |
HAMI3379 用途与合成方法
|
CysLT 2
|
In a CysLT
2
receptor reporter cell line, HAMI 3379 antagonizes leukotriene D
4
- (LTD
4
-) and leukotriene C
4
- (LTC
4
-) induced intracellular calcium mobilization with IC
50
values of 3.8 nM and 4.4 nM, respectively. In contrast, HAMI 3379 exhibits very low potency on a recombinant CysLT
1
receptor cell line (IC
50
>10000 nM).
HAMI 3379 (ip; 0.025-0.4 mg/kg; 24 hours) attenuates the acute brain injury 24 hours after middle cerebral artery occlusion (MCAO) with effective doses of 0.1-0.4 mg/kg and a therapeutic window of ∼1 hour. It attenuates the neurological deficits, and reduces infarct volume, brain edema, and neuronal loss and degeneration 24 and 72 hours after MCAO.
HAMI 3379 (infused into the aortic cannula at a rate of 1% of the total flow rate; 0.01, 0.1, 1 μM; 20 min) concentration-dependently inhibits and reverses the LTC
4
-induced perfusion pressure increase and contractility decrease.
| Animal Model: | Male Sprague-Dawley rats (250-300 g) after MCAO |
| Dosage: | 0.025, 0.05, 0.1, 0.2, 0.4 mg/kg |
| Administration: | IP; 24 hours |
| Result: | Attenuated the acute brain injury 24 hours after MCAO with effective doses of 0.1-0.4 mg/kg and a therapeutic window of ∼1 hour. |
HAMI3379 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024-11-08 | HY-112248A | 5 mg | 2300 | ||
| 2024-11-08 | HY-112248A | 10 mg | 3700 |
